Cardiovascular involvement in psoriatic arthritis;Coinvolgimento cardiovascolare nell'artrite psoriasica

Reumatismo

Volumn 63, Issue 3, 2011, Pages 148-154

  Atzeni, F ^a   Turiel, M ^b   Boccassini, L ^a   Sitia, S ^b   Tomasoni, L ^b   Battellino, M ^a   Marchesoni, A ^c   de Gennaro Colonna, V ^b   Sarzi Puttini, P ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c Istituto Ortopedico G Pint   (Italy)

Author keywords

Asymmetric dimethylarginine; Cardiovascular involvement; Psoriatic arthritis; Risk factors

Indexed keywords

ADALIMUMAB; C REACTIVE PROTEIN; CYTOKINE; D DIMER; ETANERCEPT; FIBRINOGEN; INFLIXIMAB; INTERLEUKIN 1; INTERLEUKIN 16; INTERLEUKIN 18; INTERLEUKIN 1BETA; METHOTREXATE; N(G),N(G) DIMETHYLARGININE; TOCILIZUMAB; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR INHIBITOR;

ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; COMORBIDITY; CORONARY FLOW RESERVE; CYTOKINE PRODUCTION; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG MECHANISM; ENZYME BLOOD LEVEL; HUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PSORIATIC ARTHRITIS; RHEUMATOID ARTHRITIS; RISK FACTOR;

EID: 80855136364     PISSN: 00487449     EISSN: None     Source Type: Journal    
DOI: 10.4081/reumatismo.2011.148     Document Type: Article

References (59)

1. Sheeb M, Uramoto KM, Gibson LE, O'fallon WM, Gabriel SE. The epidemiology of psoriatic arthritis in Olmsted County, Minnesota, USA, 1982-1991. J Rheumatol 2000; 27: 1247-1250.
2. Wong K, Gladman DD, Husted J, Long JA, Farewell VT. Mortality studies in psoriatic arthritis: results from a single outpatient clinic. I. Causes and risk of death. Arthritis Rheum 1997; 40: 1868-1872.
3. Gladman DD, Farewell VT, Wong K, Husted J. Mortality studies in psoriatic arthritis: results from a single outpatient center. II. Prognostic indicators for death. Arthritis Rheum 1998; 41: 1103-1110.
4. Gladman DD, Ang M, Su L, Tom BD, Schentag CT, Farewell VT. Cardiovascular morbidity in psoriatic arthritis. Ann Rheum Dis 2009; 68: 1131-1135.
5. Mallbris L, Akre O, Branath F, Yin L, Lindelof B, Ekbom A, et al. Increased risk for cardiovascular mortality in psoriatic inpatients but not outpatients. Eur J Epidemiol 2004; 19: 225-230.
6. Han C, Robinson DW Jr, Hackett MV, Paramore LC, Fraeman KH, Bala MV. Cardiovascular disease and risk factors in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. J Rheumatol 2006; 33: 2167-2172.
7. Kimhi O, Caspi D, Bornstein NM, Maharshak N, Gur A, Arbel Y, et al. Prevalence and risk factors of atherosclerosis in patients with psoriatic arthritis. Semin Arthritis Rheum 2007; 36: 203-209.
8. Jones SM, Harris CPD, Lloyd J, Stirling CA, Reckless JPD, McHugh NJ. Lipoproteins and their subfractions in psoriatic arthritis: identification of an atherogenic profile with active joint disease. Ann Rheum Dis 2000; 59: 904-909.
9. Brustein DM, Scher RK, Auerbach R. Hyperlipoproteinaemia and psoriasis. Lancet 1976; 1: 154.
10. Reynoso-von Drateln C, Martinez-Abundis E, Balcazar-Munoz BR, Bustos-Saldana R, Gonzalez-Ortiz M. Lipid profile, insulin secretion, and insulin sensitivity in psoriasis. J AmAcad Dermatol 2003; 48: 882-885.
11. Gonzalez-Gay MA, Gonzalez-Juanatey C, Vazquez-Rodriguez TR, Gomez-Acebo I, Miranda-Filloy JA, Paz-Carreira J, et al. Asymptomatic Hyperuricemia and Serum Uric Acid Concentration Correlate with Subclinical Atherosclerosis in Psoriatic Arthritis Patients Without Clinically Evident Cardiovascular Disease. Semin Arthritis Rheum 2009; 39:157-162.
12. Gonzalez-Juanatey C, Llorca J, Miranda-Filloy JA, Amigo-Diaz E, Testa A, Garcia-Porrua C, et al. Endothelial dysfunction in psoriatic arthritis patients without clinically evident cardiovascular disease or classic atherosclerosis risk factors. Arthritis Rheum 2007; 57: 287-293.
13. Gonzalez-Juanatey C, Llorca J, Amigo-Diaz E, Dierssen T, Martin J, Gonzalez-Gay MA. High prevalence of subclinical atherosclerosis in psoriatic arthritis patients without clinically evident cardiovascular disease or classic atherosclerosis risk factors. Arthritis Rheum 2007; 57: 1074-1080.
14. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH Franklin BA, et al, for the American Heart Association and National Heart, Lung, and Blood Institute. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute scientific statement. Circulation 2005; 112: 2735-2752.
15. McNeill AM, Rosamond WD, Girman CJ, Golden SH, Schmidt MI, East HE, et al. The metabolic syndrome and 11-year risk of incident cardiovascular disease in the atherosclerosis risk in communities study. Diabetes Care 2005; 28: 385-390.
16. Mok CC, Ko GT, Ho LY, Yu KL, Chan PT, To CH. Prevalence of atherosclerotic risk factors and the metabolic syndrome in patients with chronic inflammatory arthritis. Arthritis Care Res (Hoboken) 2011; 63: 195-202.
17. Atzeni F, Turiel M, Caporali R, Cavagna L, Tomasoni L, Sitia S, et al. The effect of pharmacological therapy on the cardiovascular system of patients with systemic rheumatic diseases. Autoimmun Rev 2010; 9: 835-839.
18. Hahn BH, Grossman J, Chen W, McMahon M. The pathogenesis of atherosclerosis in autoimmune rheumatic diseases: roles of inflammation and dyslipidemia. J Autoimmun 2007; 28: 69-75.
19. Wolfe F, Michaud K. the risk of myocardial infarction and pharmacologic and non-pharmacologic myocardial infarction predictors in rheumatoid arthritis: a cohort and nested casecontrol analysis. Arthritis Rheum 2008; 58: 2612-2621.
20. Gisondi P, Girolomoni C. Psoriasis and atherothrombotic diseases: disease-specific and nondisease-specific risk factors. Semin Thromb Hemost 2009; 35: 313-324.
21. Sarzi-Puttini P, Atzeni F, Gerli R, Bartoloni E, Doria A, Barskova T, et al. Cardiac involvement in systemic rheumatic diseases: An update. Autoimmun Rev 2010; 9: 849-852.
22. van Kuijk AW, Reinders-Blankert P, Smeets TJ, Dijkmans BA, Tak PP. Detailed analysis of the cell infiltrate and the expression of mediators of synovial inflammation and joint destruction in the synovium of patients with psoriatic arthritis: implications for treatment. Ann Rheum Dis 2006; 65: 1551-1557.
23. Danning CL, Illei GG, Hitchon C, Greer MR, Boumpas DT, McInnes IB. Macrophage-derived cytokine and nuclear factor kappaB p65 expression in synovial membrane and skin of patients with psoriatic arthritis. Arthritis Rheum 2000; 43: 1244-1256.
24. Kruithof E, Baeten D, De RL, Vandooren B, Foell D, Roth J, et al Synovial histopathology of psoriatic arthritis, both oligo and polyarticular, resembles spondyloarthropathy more than it does rheumatoid arthritis. Arthritis Res Ther 2005; 7 R569-R580.
25. Silva LC, Ortigosa LC, Benard G. Anti-TNF-α agents in the treatment of immune-mediated inflammatory diseases: mechanisms of action and pitfalls. Immunotherapy 2010; 2: 817-833.
26. Popa C, Netea MG, van Riel PL, van der Meer JW, Stalenhoef AF. The role of TNF-alpha in chronic inflammatory conditions, intermediary metabolism, and cardiovascular risk. J Lipid Res 2007; 48: 751-762.
27. Dixon WG, Symmons DP.What effects might anti-TNFalpha treatment be expected to have on cardiovascular morbidity and mortality in rheumatoid arthritis? A review of the role of TNFalpha in cardiovascular pathophysiology. Ann Rheum Dis 2007; 66: 1132-1136.
28. Popa C, van den Hoogen FH, Radstake TR, Netea MG, Eijsbouts AE, den Heijer M, et al. Modulation of lipoprotein plasma concentrations during long-term anti-TNF therapy in patients with active rheumatoid arthritis. Ann Rheum Dis 2007; 66: 1503-1507.
29. Ingegnoli F, Fantini F, Griffini S, Soldi A, Meroni PL, Cugno M. Anti-tumor necrosis factor alpha therapy normalizes fibrinolysis impairment in patients with active rheumatoid arthritis. Clin Exp Rheumatol 2010; 28: 254-257.
30. Ingegnoli F, Fantini F, Favalli EG, Soldi A, Griffini S, Galbiati V, et al. Inflammatory and prothrombotic biomarkers in patients with rheumatoid arthritis: effects of tumor necrosis factor-alpha blockade. J Autoimmun 2008; 31: 175-179.
31. Moots RJ, Ostor AJK, IJD Will. treatment of rheumatoid arthritis with an IL-6R inhibitor help facilitate the 'age of remission'? Expert Opin Investig Drugs 2009; 18: 1687-1699.
32. Oldfield V, Dhillon S, Plosker GL. Tocilizumab. A review of its use in the management of rheumatoid arthritis. Drugs 2009; 69: 609-632.
33. Atzeni F, Sarzi-Puttini P, Vena GA. Resistant cases of psoriatic arthritis: how to manage them. J Rheumatol 2009; 83: 73-S75.
34. Angel K, Provan SA, Gulseth HL, Mowinckel P, Kvien TK, Atar D. Tumor necrosis factoralpha antagonists improve aortic stiffness in patients with inflammatory arthropathies: a controlled study. Hypertension 2010; 55: 333-338.
35. Sattar N, Crompton P, Cherry L, Kane D, Lowe G, McInnes IB. Effects of tumor necrosis factor blockade on cardiovascular risk factors in psoriatic arthritis: a double-blind, placebo- controlled study. Arthritis Rheum 2007; 56: 831-839.
36. Bannwarth B, Richez C. Clinical safety of tocilizumab in rheumatoid arthritis. Expert Opin Drug Saf 2011; 10: 123-131.
37. Anthony S, Leiper J, Vallance P. Endogenous production of nitric oxide synthase inhibitors. Vasc Med 2005; 10: S3-S9.
38. Miyazaki H, Matsuoka H, Cooke JP et al. Endogenous nitric oxide synthase inhibitor: a novel marker of atherosclerosis. Circulation 1999; 99: 1141-1146.
39. Vallance P. Importance of asymmetrical dimethylarginine in cardiovascular risk. Lancet 2001; 358: 2096-2097.
40. Anthony S, Leiper J, Vallance P. Endogenous production of nitric oxide synthase inhibitors. Vasc Med 2005; 10: S3-S9.
41. Boger RH, Bode-Boger SM, Thiele W, Junker W, Alexander K, Frolich JC. Biochemical evidence for impaired nitric oxide synthesis in patients with peripheral arterial occlusive disease. Circulation 1997; 95: 2068-2074.
42. Lundman P, Eriksson MJ, Stuhlinger M, Cooke JP, Hamsten A, Tornvall P. Mild-tomoderate hypertriglyceridemia in young men is associated with endothelial dysfunction and increased plasma concentrations of asymmetric dimethylarginine. J Am Coll Cardiol 2001; 38: 111-116.
43. Boger RH, Bode-Boger SM, Thiele W, Junker W, Alexander K, Frolich JC. Biochemical evidence for impaired nitric oxide synthesis in patients with peripheral arterial occlusive disease. Circulation 1997; 95: 2068-2074.
44. Surdacki A, Nowicki M, Sandmann J, Tsikas D, Boeger RH, Bode-Boeger SM, et al. Reduced urinary excretion of nitric oxide metabolites and increased plasma levels of asymmetric dimethylarginine in men with essential hypertension. J Cardiovasc Pharmacol 1999; 33: 652-658.
45. Stuhlinger MC, Abbasi F, Chu JW, Lamendola C, McLaughlin TL, Cooke JP, et al. Relationship between insulin resistance and an endogenous nitric oxide synthase inhibitor. JAMA 2002; 287: 1420-146.
46. Valkonen VP, Paiva H, Salonen JT, Lakka TA, Lehtimaki T, Laakso J, et al. Risk of acute coronary events and serum concentration of asymmetrical dimethylarginine. Lancet 2001; 358: 2127-218.
47. Bae SW, Stuhlinger MC, Yoo HS, Yu KH, Park HK, Choi BY, et al. Plasma asymmetric dimethylarginine concentrations in newly diagnosed patients with acute myocardial infarction or unstable angina pectoris during two weeks of medical treatment. Am J Cardiol 2005; 95: 729-733.
48. MacAllister RJ, Rambausek MH, Vallance P, Williams D, Hoffmen KH, Ritz E. Concentration of dimethyl-l-arginine in the plasma of patients with end-stage renal failure. Nephrol Dial Transplant 1996; 11: 2449-2452.
49. Turiel M, Atzeni F, Tomasoni L, de Portu S, Delfino L, Bodini BD, et al. Non-invasive assessment of coronary flow reserve and ADMA levels: a case-control study of early rheumatoid arthritis patients. Rheumatology (Oxford). 2009; 48: 834-839.
50. Atzeni F, Sarzi-Puttini P, De Blasio G, Delfino L, Tomasoni L, Turiel M. Preclinical impairment of coronary flow reserve in patients with rheumatoid arthritis. Ann N Y Acad Sci. 2007; 1108: 392-397.
51. Atzeni F, Sarzi-Puttini P, Sitia S, Tomasoni L, Gianturco L, Battellino M, et al. Coronary flow reserve and ADMA levels: new parameters for identifying subclinical atherosclerosis in patients with psoriatic arthritis. J Rheumatol 2011 (in press).
52. Turiel M, Peretti R, Sarzi-Puttini P, Atzeni F, Doria A. Cardiac imaging techniques in systemic autoimmune diseases. Lupus 2005; 14: 727-731.
53. Tam LS, Shang Q, Li EK, Tomlinson B, Chu TT, Li M, et al. Subclinical carotid atherosclerosis in patients with psoriatic arthritis. Arthritis Rheum 2008; 59: 1322-1331.
54. Turiel M, Tomasoni L, Sitia S, Cicala S, Gianturco L, Ricci C, et al. Effects of long-term disease-modifying antirheumatic drugs on endothelial function in patients with early rheumatoid arthritis. Cardiovasc Ther 2010; 28: 53-64.
55. Quinn MA, Cox S. The evidence for early intervention. Rheum Dis Clin North Am 2005; 31: 575-589.
56. Choi HK, Hernan MA, Seeger JD, Robins JM, Wolfe F. Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study. Lancet 2002; 359: 1173-1177.
57. Tam L, Li EK, Shang Q, Tomlinson B, Chu TT, Li M, et al. TNF-alpha blockade is associated with reduction of carotid intima-media thickness for patients with active psoriatic arthritis - a pilot study. Ann Rheum Dis 2009; 68 (Suppl 3): 659.
58. Mazlan SA, bin Mohamed Said MS, Hussein H, binti Shamsuddin K, Shah SA, Basri H. A study of intima media thickness and their cardiovascular risk factors in patients with psoriatic arthritis. Acta Medica (Hradec Kralove). 2009; 52: 107-116.
59. Di Minno MN, Iervolino S, Peluso R, Scarpa R, Di Minno G; CaRRDs study group. Carotid intima-media thickness in psoriatic arthritis: differences between tumor necrosis factor-α blockers and traditional disease-modifying antirheumatic drugs. Arterioscler Thromb Vasc Biol 2011; 31: 705-72.